ZNTL Stock Recent News

Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients, the ORR achieved was 37%. Initiation of a clinical trial using azenosertib for 1st-line maintenance platinum-sensitive ovarian cancer patients expected in 2025; Trial design to be revealed in the 2nd half of 2024.

The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Zentalis management will participate in several upcoming investor conferences:

Zentalis Pharmaceuticals, Inc. (ZNTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zentalis Pharmaceuticals is positioned to become an oncology leader with its lead drug candidate, azenosertib, showing promising results in difficult-to-treat cancers. The company's financial health is strong, with a healthy cash reserve that will sustain operations until 2026. ZNTL is strategically expanding azenosertib's utility across wider indications and forming partnerships to reduce clinical trial risks and increase the likelihood of success.

Zentalis is a biotech company focused on developing Azenosertib, a Wee1 inhibitor, for ovarian cancer. The company has faced stock sell-offs due to mixed data from clinical trials of Azenosertib in combination with chemotherapy, and as a monotherapy. Zentalis believes Azenosertib has potential and plans to submit a New Drug Application in 2026, but analysts have downgraded expectations.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's financials show a solid cash position and efficient allocation of resources. Zentalis has a diverse pipeline of oncological therapies in various stages of clinical trials, targeting different types of cancer.

Shares of Zentalis Pharmaceuticals Inc (US:ZNTL) are cooling off a bit Thursday after yesterday's 4% rise capped a five-day rally of 17.8%.

Zentalis is a clinical-stage biotech that is focusing on cancer therapies. The stock is up more than 29% this year.

Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib